Literature DB >> 30935689

Apelin-13 attenuates early brain injury following subarachnoid hemorrhage via suppressing neuronal apoptosis through the GLP-1R/PI3K/Akt signaling.

Yao Liu1, Tongyu Zhang2, Yanbin Wang2, Pei Wu2, Yuchen Li2, Chunlei Wang2, Shancai Xu2, Huaizhang Shi3.   

Abstract

Apelin, an endogenous ligand for the orphan G-protein-coupled receptor APJ, possesses anti-apoptotic and neuroprotective properties. It has been shown to be a protective factor for different types of central nervous system insults, such as ischemia and traumatic brain injury. Here, we investigated the effects of apelin-13 on early brain injury (EBI) following subarachnoid hemorrhage (SAH), and the underlying molecular mechanisms involved. Apelin-13 was delivered to rats via intracerebroventricular administration. Neurological scores, brain water content and neuronal apoptosis were measured 24 h after SAH. The PI3K/Akt inhibitor LY294002 or GLP-1R siRNA were injected into the lateral cerebral ventricle before induction of SAH. Changes in the expression of p-Akt, GLP-1R and apoptosis-associated proteins (Bax, Bcl-2, cleaved caspase-3) were then investigated. Results showed that the levels of GLP-1R in neurons increased significantly, reaching a peak at 24 h after the induction of SAH. Treatment with apelin-13 improved neurological deficits, as well as alleviated brain edema and apoptotic cell death. Apelin-13 was also able to increase the levels of p-Akt, GLP-1R and Bcl-2, while inhibiting the expression levels of Bax and cleaved caspase-3. The anti-apoptotic and neuroprotective effects of apelin-13 were partially reversed by addition of LY294002 or GLP-1R siRNA. These results provide evidence that apelin-13 attenuates EBI following SAH via suppressing neuronal apoptosis, and that this effect may act partially via the activation of the GLP-1R/PI3K/Akt signaling pathway.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apelin-13; Apoptosis; Early brain injury; GLP-1R; PI3K/Akt signaling; Subarachnoid hemorrhage

Year:  2019        PMID: 30935689     DOI: 10.1016/j.bbrc.2019.03.151

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Apelin-13 attenuates early brain injury through inhibiting inflammation and apoptosis in rats after experimental subarachnoid hemorrhage.

Authors:  Xiaoyan Shen; Guiqiang Yuan; Bing Li; Cheng Cao; Demao Cao; Jiang Wu; Xiang Li; Haiying Li; Haitao Shen; Zhong Wang; Gang Chen
Journal:  Mol Biol Rep       Date:  2022-01-09       Impact factor: 2.316

Review 2.  Research Progress on Mechanism of Neuroprotective Roles of Apelin-13 in Prevention and Treatment of Alzheimer's Disease.

Authors:  Teng Wan; Mingyuan Fu; Yan Jiang; Weiwei Jiang; Peiling Li; Shouhong Zhou
Journal:  Neurochem Res       Date:  2021-09-13       Impact factor: 3.996

3.  Apelin alleviated neuroinflammation and promoted endogenous neural stem cell proliferation and differentiation after spinal cord injury in rats.

Authors:  Qing Liu; Shuai Zhou; Xiao Wang; Chengxu Gu; Qixuan Guo; Xikai Li; Chunlei Zhang; Naili Zhang; Luping Zhang; Fei Huang
Journal:  J Neuroinflammation       Date:  2022-06-20       Impact factor: 9.587

Review 4.  The mechanism and relevant mediators associated with neuronal apoptosis and potential therapeutic targets in subarachnoid hemorrhage.

Authors:  Qi Tian; Sheng Liu; Shou-Meng Han; Wei Zhang; Xian-Yao Qin; Jun-Hui Chen; Cheng-Li Liu; Yu-Jia Guo; Ming-Chang Li
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

Review 5.  The beneficial roles of apelin-13/APJ system in cerebral ischemia: Pathogenesis and therapeutic strategies.

Authors:  Jiabin Li; Zhang Chen; Jingyu Chen; Yue Yu
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

6.  Eucalyptol ameliorates early brain injury after subarachnoid haemorrhage via antioxidant and anti-inflammatory effects in a rat model.

Authors:  Gang Xu; Junsheng Guo; Chunming Sun
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.